In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...